Many clinical trials rely on patient-reported outcomes to determine whether drugs are working, but with disparate methods employed across the industry, it can be difficult to compare the results from one study with those of another. With that in mind, the FDA has recruited CRO giant Icon to help develop an industry standard for patient polling in antibacterial R&D.
CRO giant Icon charted double-digit revenue growth in the third quarter, chugging toward its best-ever year and lifting its earnings projections in the process.
CRO magnate Icon and and eClinical outfit Medidata are pooling their resources to offer a combined platform for patient-reported outcomes in clinical trials, touting their technology as faster and more effective in surveying participants.
CRO giant Icon continued its steady progress with another double-digit quarter of sales growth, piling up revenue with hopes of clearing $1.5 billion this year.
Pfizer and Roche are the latest pharma heavyweights to join Icon's consortium of drugmakers working to flesh out new technology for adaptive clinical trials, allowing study sponsors to react to results in real time and maximize efficacy.
Global CRO Icon has deepened its longstanding relationship with Cambridge University, agreeing to lead a class on pricing and market access for new drugs.
Irish CRO Icon has closed out its $143.5 million acquisition of Aptiv Solutions, a deal designed to amp up its technology and expand its presence in Japan.
CRO Icon posted another double-digit revenue jump in its fiscal first quarter, and now the Irish outfit is upping its annual guidance, counting on M&A and an expanding market share to pad its profits.
When Big Pharma execs talk up "synergies" to convince shareholders to buy into mergers, they mean, in part, consolidating contractors. And, with all the megadeals rumored and real surfacing over the past week, CROs could be in for a revenue haircut as the drug business realigns.
CRO giant Icon has agreed to trade $143.5 million for Aptiv Solutions, looking to complement its own technology in complex trial design and expand its presence in Japan.